Compare AbbVie Inc (ABBV) vs VF Corp (VFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs VF Corp — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while VF Corp trades at $16.02 (market cap $6.45B). The key difference: AbbVie Inc is far larger — about 69.8× VF Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | VFC | |
|---|---|---|
Market Cap | $449.91B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $21.55 |
52-Week Low | $184.85 | $11.66 |
Enterprise Value | $513.38B | $10.60B |
Dividend Yield | 2.72% | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
VFC trades at $16.45, up 0.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings showed a Q1 2026 miss after two prior beats, while revenue declined to $9.50B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M. Analyst consensus is mixed with a $20.00 price target, and news highlights focus on turnaround progress and debt reduction.
VFC's outlook hinges on executing its brand turnaround, particularly at Vans, with guided revenue growth for 2027 offering potential upside. Risks include weak consumer confidence and high leverage, though deleveraging efforts are underway. The stock presents a value opportunity with a low P/S of 0.68, but investors face near-term volatility from earnings uncertainty and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
